Best Dermatology Companies in United Kingdom
The 36 best Dermatology companies in United Kingdom in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Avita Medical.
- Dermatology Market Size Worth USD 2.04 Billion in 2030
Ranked: Best Dermatology companies in United Kingdom
| # | Company | Disclosed funding | Last round | Employees | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Avita Medical Regenerative and Respiratory Medicine product company 64Funding top 19%Market top 35%News top 35%Moat top 38% All 11 signals ▾Fundingtop 19% Markettop 35% Newstop 35% Moattop 38% Techtop 39% Talenttop 40% Growthtop 42% Globaltop 44% Fin. healthtop 48% Patentsbottom 45% Innovationbottom 42% Funding: Raised $205M across 13 rounds · 13 rounds over 17 yrs (0.8/yr) Market: 108 employees (top 17% of Life Sciences) · Revenue ~$71.6M rank vs industry peers · Fliar Intelligence Index 64/100 | $205M | 13 mo ago | 108 108 → 255 (+136%) | Michael Perry CEO | DrupalApple iCloud MailPHP+35 | 26 patents Automated tissue processing and cell suspension preparation for regenerative medicine | — |
| 2 | Sitryx Biotechnology company focused on immunometabolism, developing therapies | $69M | 38 mo ago | 17 | Paul-Peter Tak Co-Founder & Director | Node.jsNext.jsReact+8 | — | — |
| 3 | York Pharma Develop drugs for dermatological disorders | $44M | 218 mo ago | 23 | — | — | 26 patents Advanced pharmaceutical formulations and skin barrier‑enhancing drug delivery technologies | — |
| 4 | Ziarco Developer of treatments for chronic inflammatory skin disorders like eczema | $41M | 142 mo ago | 3 | — | — | — | — |
| 5 | Midatech Provider of novel drug delivery technologies for the treatment of diseases | $16M | 43 mo ago | 40 40 → 24 (-40%) | — | — | 204 patents Targeted drug delivery via cyclodextrin and nanoparticle formulations for oncology and immunotherapy | 1 expansion |
| 6 | Michelson Diagnostics Point-of-care Optical Coherence Tomography(OCT) device for dermatology | $15M | 139 mo ago | 11 | — | — | 80 patents Advanced OCT image processing and analysis for medical diagnostic imaging | — |
| 7 | Intercytex Developer of cell-based therapies for the repair and regeneration of skin and hair | $13M | 253 mo ago | 1 | Paul Kemp Founder & CEO | — | 48 patents Regenerative skin and hair therapies using cultured fibroblasts and hair‑inductive cells | — |
| 8 | Quality by Design Developer and manufacturer biomaterials | $13M | 75 mo ago | 44 | — | DrupalPleskPHP+15 | — | — |
| 9 | Phase Focus Provider of virtual lens that generates High definition images without high-quality lenses | $12M | 36 mo ago | 10 | Martin Humphry Chief Executive Officer | Concrete CMSPHPVimeo+15 | 135 patents Object tracking and temporal behavior analysis using 3D imaging and computer vision | — |
| 10 | Vivosight Provider of optical coherence tomography diagnostic device for dermatology | $9M | 139 mo ago | 11 | Jonathan Holmes CEO | — | — | — |
| 11 | ILC Therapeutics Developer of immunotherapeutics for the treatment cancer | $8M | 24 mo ago | 2 | Bill Stimson Founder | — | 51 patents Engineered interferon proteins and therapeutic biologics for viral infection treatment | — |
| 12 | Atopix Therapeutics Medicines to treat atopic dermatitis and severe asthma | $6M | 135 mo ago | 6 | Ugo Francesco CEO | — | 104 patents Patents concentrated in chemistry & materials | — |
| 13 | AMLo Biosciences Developer of a prognostic test for the early detection of cancer | $6M | 21 mo ago | 11 | Penny Lovat Co-Founder | — | 32 patents Diagnostic biomarkers and therapeutic antibodies for melanoma and squamous cell carcinoma | — |
| 14 | Clock.bio Developer of treatments for age-related diseases using human pluripotent stem cells | $5M | 28 mo ago | 7 | Koby Baranes Co-Founder | WordPressMySQLPHP+10 | — | — |
| 15 | Axis Three Aesthetic consultation by providing 3D patient simulation | $5M | 206 mo ago | 11 | Steve Crummey CEO | — | — | — |
| 16 | Pplus products Developer of skin regenerative therapies using blood plasma | $2M | 53 mo ago | 7 | Mitra Najafi Founder & CEO | — | — | — |
| 17 | Eykona Technologies Provider of portable 3D imaging systems for dermatological applications | $2M | 191 mo ago | — | Ron Daniel Co-Founder | — | 8 patents 3D imaging and reconstruction systems for generating volumetric visualizations | — |
| 18 | LYMA Life Provider of dietary supplements and multivitamins for overall wellness | $1M | 91 mo ago | 26 | — | ShopifySentryApple iCloud Mail+38 | 23 patents Patents concentrated in health & consumer products | 1 launch |
| 19 | Mariposa Therapeutics Developer of novel treatments for keratin-related skin disorders | $1M | 6 mo ago | 5 | Thomas Hafner Co-Founder | — | — | — |
| 20 | Curapel Specialty pharmaceutical company developing technologies for common skin conditions | $496K | 125 mo ago | — | Neil Gibbs Founder | — | — | — |
| 21 | Sinclair Manufacturer of injectable and energy-based device treatments for aesthetic purposes | — | 100 mo ago | 510 | Miguel Pardos Chief Executive Officer | Apple iCloud MailVimeoAzure Front Door+20 | — | — |
Top 12 Dermatology companies in United Kingdom
#1
Public · Cambridge, England · founded 1992 · 108 employees$204.8Mraised▾
Avita Medical develops and distributes products in Regenerative and Respiratory Medicine. The company’s regenerative and tissue-engineered products provide solutions utilizing the patient’s own skin and the regenerative capability of the human body to treat a wide range of wounds, scars and skin defects. The Regenerative group of products uses proprietary technology to create a Regenerative Epithelial Suspension RES™ – an autologous suspension comprised of the cells and wound healing factors necessary to regenerate natural healthy skin. The Regenerative group of products includes ReCell® for the treatment of burns and Maxillo-Facial procedures, ReCell® for plastics/aesthetics and ReCell® for the treatment of lower leg chronic wounds. Additionally, the company commercializes innovative medical technologies for improved medication delivery and adherence in patients suffering from chronic respiratory diseases. Key respiratory products include the Funhaler® incentive asthma spacer designed specifically for the pediatric market. The Breath-A-Tech™ range optimizes the delivery of aerosol medication in the management of Asthma and COPD
- Aug 2025Post IPO$15M
- Nov 2019Post IPO$82M
- Feb 2019Post IPO$14.4M
- Dec 2018Post IPO$8.9M
#2
Seed · Cardiff, Wales · founded 2019 · 5 employees$1Mraised▾
Developer of novel treatments for keratin-related skin disorders. It focuses on developing innovative solutions to treat these conditions. The company leverages specialist expertise in epithelial cell biology and keratin intermediate filaments to create its treatments. Collaboration is a key aspect of its approach, seeking partnerships to advance research and bring new therapies to patients lacking current cures.
- Mar 2026Seed$1M
#3
Series A · Newcastle Upon Tyne, England · founded 2017 · 11 employees$5.7Mraised▾
Developer of a prognostic test for the early detection of cancer. The company provides a prognostic test for early detection of AJCC Stage I and Stage II melanoma. The company's product includes AMBLor, a diagnostic test that is based on two protein markers, AMBRA1 and loricrin (AMLo) present in the upper layer of the epidermis.
- Nov 2024Series A$2M
- Apr 2022Series A$3.2M
- Nov 2020Series A$2M
- Oct 2018Seed$494.1K
#4
Series B · Oxford, England · founded 2018 · 17 employees$69Mraised▾
Biotechnology company focused on immunometabolism, developing therapies. The company exploits the link between immune function and metabolism to create first-in-class, disease-modifying drugs aiming for sustained remission. Their science regulates metabolic pathways in immune cells to restore balance disrupted in chronic conditions.
- Jul 2023Series B$39M
- Dec 2022Series A$3.7M
- Sep 2022Series A$11.8K
- Mar 2020Series A$9.6M
#5
Series A · Lanark, Scotland · founded 2012 · 2 employees$8.1Mraised▾
ILC Therapeutics is the developer of immunotherapeutics for cancer treatment. It has designed synthetic peptides that have affinities for receptors present on innate lymphoid cells. It uses this immunomodulation technology that increases the T cell responses against cancer cells. It also developing therapies for skin diseases such as Atopic dermatitis (AD) and Psoriasis.
- Sep 2024Series A$3.3M
- Sep 2021Series A$4.8M
- Dec 2020Seed—
#6
Seed · Cambridge, England · founded 2020 · 7 employees$5.3Mraised▾
Developer of treatments for age-related diseases using human pluripotent stem cells. This company harnesses the regenerative capabilities of these cells to identify and develop novel therapies. They utilize a unique aging model to force-age induced pluripotent stem cells (iPSCs), triggering their self-rejuvenation mechanism. Unbiased CRISPR screens then identify genes crucial for cell rejuvenation, enabling a comprehensive understanding of rejuvenation biology and the creation of new treatment approaches. The technology allows for rapid decoding of human rejuvenation biology, accelerating the development of effective therapies.
- Apr 2024Seed$5.3M
- Feb 2024Seed$4.4M
- Dec 2021Seed$205K
#7
Acquired · Sheffield, England · founded 2006 · 10 employees$12.1Mraised▾
Provider of virtual lens that generates High definition images without high-quality lenses. It develops a lensless imaging method. It also finds analytical applications in life sciences and engineering metrology and in multiple wavelength regimes like visible light, X-ray, electron, and others.
- Aug 2023Series B$191.2K
- Jul 2012Series B$5M
- Jul 2009Series A$5.7M
- Feb 2008Seed$1.2M
#8
Public · Abingdon, England · founded 2000 · 40 employees$16Mraised▾
Provider of novel drug delivery technologies for the treatment of diseases. It develops a pipeline of product candidates in clinical and pre-clinical development for diseases such as diabetes, rare cancers including brain, ovarian, liver, and pancreatic cancer, and neurological/ophthalmologic conditions. It provides in-house technology platforms for sustained release to prolong and control the release of therapeutics over an extended period of time and dissolve insoluble drugs which can be converted into liquid form and can be treated for tumor patients.
- Feb 2023Post IPO$6M
- Aug 2020Post IPO$1M
- 2020Grant (prize money)$56.1K
- Oct 2019Post IPO$3M
#9
Deadpooled · Milton Keynes, England · founded 2003 · 23 employees$44Mraised▾
York Pharma was a speciality pharmaceutical company focussed on the acquisition, development, and commercialisation of prescription dermatological products. Its clinical product pipeline comprised Abasol, an antifungal for the treatment of dermatomycoses; Sabarep for the treatment of atopic eczema and irritant contact dermatitis; and Vampex for the treatment of psoriasis. It also had preclinical programs such as YP004, for skin cancer; YP005 for hyperproliferative skin disorders such as acne; YP006 for fungal nail infections; and YP007for the treatment of vaginal candidiasis.The company appears to be closed.
- Jul 2008Post IPO$7.2M
- Oct 2006Post IPO$5.6M
#10
Acquired · Sandwich, England · founded 2012 · 3 employees$40.7Mraised▾
Developer of treatments for chronic inflammatory skin disorders like eczema. The company focuses on advancing programmes through clinical proof-of-concept studies. It develops therapies for atopic dermatitis and psoriasis. The company is developing an oral antagonist of the histamine H4 receptor. It is also developing a topical inhibitor of cPLA2.
- Nov 2014Series B$33.1M
- Oct 2012Series A$7.6M
#11
Acquired · London, England · founded 2014 · 44 employees$12.9Mraised▾
Quality by Design is a developer and manufacturer of biomaterials. The company develops medical grade collagen components using its proprietary platform. The company's product can be used for regenerative medicine, medical devices, and in vitro diagnostic products.
- May 2020Grant (prize money)—
- Jan 2019Grant (prize money)$2M
- Jan 2017Grant (prize money)$693.8K
- Jan 2016Grant (prize money)$805.8K
#12
Deadpooled · Maidstone, England · founded 2006 · 11 employees$14.9Mraised▾
Point-of-care Optical Coherence Tomography(OCT) device for dermatology. The company offers the VivoSight OCT system, a point-of-care scanning device that provides clinicians with a non-invasive tool for diagnosing several skin pathologies.
- Feb 2015Series B$3.8M
- Dec 2013Series A$3.2M
- Mar 2012Seed$955.4K
- Oct 2011Seed$3.1M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Dermatology coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.